Medtronic Cuts FY22 Revenue Growth Guidance On Organic Basis - Quick Facts

While reporting second-quarter results on Tuesday, Medtronic plc (MDT) updated its revenue growth guidance and reiterated its EPS guidance range for fiscal 2022. The company now projects fiscal 2022 revenue growth of 7-8% on an organic basis versus the prior expectation of approximately 9%. The company reiterated fiscal 2022 non-GAAP EPS guidance range of $5.65 to $5.75.

Analysts polled by Thomson Reuters expect the company to report profit per share of $5.71. Analysts' estimates typically exclude special items.

Karen Parkhill, CFO, said: "While we expect our markets to continue to be affected by the pandemic in the second half of our fiscal year, we remain focused on delivering solid revenue growth and strong earnings growth while investing in our robust pipeline."

Second quarter adjusted earnings per share increased to $1.32 from $1.02, prior year. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $1.29, for the quarter.

GAAP net income and earnings per share were $1.31 billion and $0.97, respectively, up 168% and 169%, respectively. Worldwide revenue was $7.85 billion, an increase of 3% as reported and 2% on an organic basis. Analysts on average had estimated $7.96 billion in revenue.

Shares of Medtronic plc were down 1% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT